Synthesis and Biological Evaluation of Diethylenetriamine Pentaacetic acid−Polyethylene Glycol−Folate: A New Folate-Derived, 99mTc-Based Radiopharmaceutical

Authors:

Abstract
99mTechnetium-labeled diethylenetriamine pentaacetic acid−polyethylene glycol−folate (DTPA−PEG−folate) was synthesized and tested as a radiopharmaceutical agent, which targeted the lymphatic system with metastatic tumor. Folic acid was reacted with H2N−PEG−NH2 to yield H2N−PEG−folate. After purification by anion-exchange chromatography, the product was reacted with cyclic DTPA. By removal of unreacted DTPA by size-exclusion chromatography, DTPA−PEG−Folate was obtained. Fluorescein-5-isothiocyanate (FITC)-labeled DTPA−PEG−folate and DTPA−PEG−OCH3 were prepared via a dicyclohexylcarbodiimide-mediated coupling. In vitro competitive binding test showed that the uptake of [125I] folic acid was inhibited by DTPA−PEG−folate and the 50% inhibitory concentration was 4.37 pmol/L (R2 = 0.9922). The relative affinity of DTPA−PEG−FITC was 0.18 for human folate receptor comparing with folic acid. In cultured tumor cells, uptake of fluorescence-labeled DTPA−PEG−folate was found to increase significantly in folate-deficient medium compared with that of untargeted DTPA−PEG−OCH3 and FITC−ethylenediamine. The competition with free folic acid blocked the cell uptake of DTPA−PEG−folate. These results confirmed the DTPA−PEG−folate entered into KB cells through the folate receptor endocytosis pathway in vitro. The radiolabeled yield of [99mTc] DTPA−PEG−folate was in excess of 98%, and specific activities of 7.4 kBq (0.2μCi/μg) were achieved. After subcutaneous injection, [99mTc] DTPA−PEG−folate exhibited an initial increase and successive decline of accumulation in popliteal nodes in normal Wistar rats. Expect for the kidney, uptake by other tissues was rather low. In a normal rabbit imagine study, the lymphatic vessels were readily visualized by single-photon-emmission computed tomography following subcutaneous injection of [99mTc] DTPA−PEG−folate. In conclusion, the [99mTc] DTPA−PEG−folate conjugate may have a potential as a lymphatic tumor-targeted radiopharmaceutical.

This publication has 12 references indexed in Scilit: